Cutia Therapeutics (HKG:2487) said its CU-40102 topical finasteride spray received marketing approval from Macao's Pharmaceutical Administration Bureau for the treatment of androgenetic alopecia, according to a Monday Hong Kong bourse filing.
The approval follows marketing authorizations from China's National Medical Products Administration and Hong Kong's Department of Health.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.